14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ESP vs VREX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Espey Mfg. & Electronics Corp (ESP) captures the overall head-to-head institutional edge over Varex Imaging Corporation (VREX) on higher Unified Composite conviction (39.8/100 SELL vs. 54.8/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while VREX wins 3–2 across the 6-pillar growth and valuation breakdown. ESP trades at $37.03 (10.0x Forward P/E, 24.4% operating margin) versus VREX at $18.10 (16.9x Forward P/E, 8.3% operating margin).
Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (54.8/100 HOLD vs. ESP 39.8/100 SELL), ESP captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (24.4% vs. 8.3% operating margin) and revenue trajectory (+16.7% vs. +3.7% YoY).
Technical & Structure Timing Caution: ESP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile VREX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ESP vs VREX. Trailing 12-month operating profitability (ESP 24.4% vs VREX 8.3%) and valuation multiples (ESP 10.0x vs VREX 16.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $770.3M market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment26.0% of Rev ($225M)
90D Engineering Disclosures0 Published
Investor FAQ ESP vs VREX Key Questions & Quantitative Answers
As of Nov 20, 2026, Espey Mfg. & Electronics Corp (ESP) captures the overall head-to-head institutional edge over Varex Imaging Corporation (VREX) on higher Unified Composite conviction (39.8/100 SELL vs. 54.8/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while VREX wins 3–2 across the 6-pillar growth and valuation breakdown. ESP trades at $37.03 (10.0x Forward P/E, 24.4% operating margin) versus VREX at $18.10 (16.9x Forward P/E, 8.3% operating margin). Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (54.8/100 HOLD vs. ESP 39.8/100 SELL), ESP captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (24.4% vs. 8.3% operating margin) and revenue trajectory (+16.7% vs. +3.7% YoY). Technical & Structure Timing Caution: ESP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile VREX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VREX leads the Growth & Scale pillar: ESP posts +16.7% YoY revenue growth and -1.3% YoY earnings growth on $48M TTM revenue (34.2% gross margin, 24.4% operating margin), compared with VREX at +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin). On trailing 12-month operating scale, ESP generates $48M in USD-normalized revenue versus $865M for VREX. In operating R&D and SG&A reinvestment, ESP deploys 9.8% of Rev ($4.7M) (0 90-day corporate R&D disclosures) versus 26.0% of Rev ($225M) (0 disclosures) for VREX.
ESP screens cheaper on headline valuation multiples. ESP trades at 10.0x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.4x EV/Revenue (9.3% FCF margin), whereas VREX trades at 16.9x Forward P/E, 34.2x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ESP (20.1% ROE) versus VREX (4.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ESP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 67% Vol realized risk). By comparison, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 5% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.